Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 17.83 | 12.15 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (10.86) | (11.58) | |
P/B ratio |
— | — | 3.92 | 2.88 | |
Price to Tangible BV |
— | — | 7.45 | 4.31 | |
EV/Sales |
— | — | 15.86 | 9.83 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (2.71) | (2.43) | |
EV/FCF |
— | — | (2.66) | (2.39) | |
Quick Ratio |
8.22 | 2.87 | 4.57 | 6.23 | |
Current Ratio |
8.57 | 3.36 | 4.91 | 6.66 | |
Net Debt/EBITDA |
3.73 | 1.59 | 2.50 | 3.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.12 | 0.16 | |
Operating CF/Net income |
1.05 | 1.01 | 0.81 | 0.84 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 67,013.79% | 1,872.41% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 28,850.57% | 721.11% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 3,433.33% | 90.42% | |
Graham Net Nets |
— | — | 0.26 | 0.35 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (37.72%) | (35.85%) | |
Free Cash Flow Yield |
— | — | (33.44%) | (33.88%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.03 | |
Operating CF per Share |
(0.68) | (0.87) | (0.73) | (0.70) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.68) | (0.87) | (0.73) | (0.70) | |
Cash per Share |
2.43 | 1.40 | 2.31 | 2.95 | |
Shareholders Equity per Share |
2.24 | 1.15 | 2.02 | 2.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 1.15 | 2.02 | 2.81 | |
Free Cash Flow |
(6.92) | (8.02) | (6.58) | (6.47) | |
Working Capital |
22.96 | 10.62 | 18.22 | 26.01 | |
Net Current Asset Value |
22.96 | 10.62 | 18.22 | 26.01 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 1.34 | 0.81 | |
Average Payables |
1.27 | 2.07 | 1.48 | 1.22 | |
Average Assets |
32.04 | 26.85 | 32.98 | 39.75 | |
Average Common Equity |
28.20 | 22.63 | 28.71 | 35.82 |
Columns are period end dates